Patents Assigned to Infectious Disease Research Institute
-
Patent number: 11266602Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.Type: GrantFiled: May 15, 2017Date of Patent: March 8, 2022Assignee: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
-
Patent number: 11173126Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.Type: GrantFiled: May 31, 2017Date of Patent: November 16, 2021Assignee: Infectious Disease Research InstituteInventors: Neal Van Hoeven, Traci Mikasa, Christopher B. Fox, Anwar Ahniyaz, Mark T. Orr, Amit Khandhar
-
Patent number: 11141377Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.Type: GrantFiled: June 15, 2018Date of Patent: October 12, 2021Assignee: Infectious Disease Research InstituteInventors: Christopher B. Fox, Amit Praful Khandhar, Neal Van Hoeven, Jesse H. Erasmus, Susan S. Lin
-
Patent number: 11135281Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.Type: GrantFiled: July 7, 2017Date of Patent: October 5, 2021Assignees: Hawaii Biotech, Inc., Infectious Disease Research InstituteInventors: David E. Clements, Neal Van Hoeven
-
Patent number: 11091521Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.Type: GrantFiled: November 16, 2017Date of Patent: August 17, 2021Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
-
Patent number: 10940198Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.Type: GrantFiled: December 20, 2017Date of Patent: March 9, 2021Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Hyo Jung Nam, Eun Mi Kim, Duck Hyang Shin, Steven G. Reed, Kang Il Yoo, Sung Jun Hong
-
Publication number: 20200338180Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.Type: ApplicationFiled: September 15, 2017Publication date: October 29, 2020Applicant: Infectious Disease Research InstituteInventors: Steven G. REED, Malcolm S. Duthie
-
Patent number: 10792359Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: January 19, 2018Date of Patent: October 6, 2020Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Patent number: 10765736Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: November 28, 2017Date of Patent: September 8, 2020Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20200148729Abstract: Provided herein are fusion polypeptides comprising at least two Mycobacterial antigens, wherein one Mycobacterial antigen is a strong central memory T cell activator, and wherein one Mycobacterial antigen is a strong effector memory T cell activator. Also provided herein are methods of making and using such fusion polypeptides for the prevention or treatment of a secondary Mycobacterium tuberculosis infection as well as for the prevention or treatment of a nontuberculous Mycobacterium infection in a mammal.Type: ApplicationFiled: May 19, 2017Publication date: May 14, 2020Applicant: Infectious Disease Research InstituteInventor: Rhea N. Coler
-
Publication number: 20200138715Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.Type: ApplicationFiled: May 15, 2017Publication date: May 7, 2020Applicants: Infectious Disease Research Institute, University of Virginia Patent FoundationInventors: Christopher B. Fox, Susan S. Lin, Darrick Carter, Neal Van Hoeven, Mayuresh M. Abhyankar, William A. Petri
-
Patent number: 10632191Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1. L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.Type: GrantFiled: October 10, 2017Date of Patent: April 28, 2020Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20200085757Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle N ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.Type: ApplicationFiled: May 17, 2017Publication date: March 19, 2020Applicant: Infectious Disease Research InstituteInventors: Neal Van Hoeven, Traci Mikasa, Christopher B. Fox, Anwar Ahniyaz, Mark T. Orr, Amit Khandhar
-
Publication number: 20200038498Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.Type: ApplicationFiled: September 10, 2018Publication date: February 6, 2020Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Rhea N. Coler
-
Publication number: 20190328868Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.Type: ApplicationFiled: December 20, 2017Publication date: October 31, 2019Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Hyo Jung NAM, Eun Mi KIM, Duck Hyang SHIN, Steven G. REED, Kang Il YOO, Sung Jun HONG
-
Publication number: 20190142935Abstract: Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.Type: ApplicationFiled: May 11, 2017Publication date: May 16, 2019Applicant: Infectious Disease Research InstituteInventor: Christopher B. Fox
-
Publication number: 20180221470Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: November 28, 2017Publication date: August 9, 2018Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20180170975Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.Type: ApplicationFiled: November 16, 2017Publication date: June 21, 2018Applicant: Infectious Disease Research InstituteInventors: Steven G. REED, Rhea N. COLER, Gregory C. IRETON, Sylvie BERTHOLET
-
Patent number: 9987355Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: June 28, 2013Date of Patent: June 5, 2018Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Patent number: 9950063Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: December 23, 2014Date of Patent: April 24, 2018Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter